Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|October 15, 2012
Proposed "Patient Bill of Rights for Prescription Drugs" under ACA
The ACA has led to some early reforms popularly known as "The Patient Bill of Rights." Here's a proposal for a similar platform specifically addressing Rx drugs.
Advertisement
Advertisement
Related to this article
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
3
FDA Approves Onswik Weekly Insulin for Adults With T2D
4
Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation
5